{"transactions":[{"id":3079111,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":147729,"kind":"organization","name":"Picularium, LLC","position":1,"cik":"0001817110","reported_name":"Picularium, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82380,"kind":"person","name":"SHAW DAVID E","position":2,"cik":"0001023870","reported_name":"SHAW DAVID E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock, $0.001 par value per share","published_at":"2020-07-21T17:34:33.000Z","date":"2020-07-20","kind":"exercise","acquired":false,"shares":1651471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Issuer Series C Preferred Stock, $0.001 par value per share, automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .2985366 of a share of Common Stock for each share of Series C Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Relay Therapeutics, Inc. (\"Issuer\") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Relay Therapeutics, Inc. (\"Issuer\") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Relay Therapeutics, Inc. (\"Issuer\") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock,$0.001 par value per share","underlying_shares":465082},"source":{"system":"sec-edgar","filing":"0000899243-20-019815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1023870/000089924320019815/doc4.xml","form_type":"4"}},{"id":3079110,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":147729,"kind":"organization","name":"Picularium, LLC","position":1,"cik":"0001817110","reported_name":"Picularium, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82380,"kind":"person","name":"SHAW DAVID E","position":2,"cik":"0001023870","reported_name":"SHAW DAVID E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock, $0.001 par value per share","published_at":"2020-07-21T17:34:33.000Z","date":"2020-07-20","kind":"exercise","acquired":false,"shares":9999999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Relay Therapeutics, Inc. (\"Issuer\") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Relay Therapeutics, Inc. (\"Issuer\") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Relay Therapeutics, Inc. (\"Issuer\") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Relay Therapeutics, Inc. (\"Issuer\") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock,$0.001 par value per share","underlying_shares":2816171},"source":{"system":"sec-edgar","filing":"0000899243-20-019815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1023870/000089924320019815/doc4.xml","form_type":"4"}},{"id":3079109,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":147729,"kind":"organization","name":"Picularium, LLC","position":1,"cik":"0001817110","reported_name":"Picularium, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82380,"kind":"person","name":"SHAW DAVID E","position":2,"cik":"0001023870","reported_name":"SHAW DAVID E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2020-07-21T17:34:33.000Z","date":"2020-07-20","kind":"exercise","acquired":true,"shares":3281253,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Relay Therapeutics, Inc. (\"Issuer\") Series A Preferred Stock, $0.001 par value per share, automatically converted into shares of Issuer Common Stock, $0.001 par value per share (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock at a conversion rate of .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any."}],"balance_after":3281253,"source":{"system":"sec-edgar","filing":"0000899243-20-019815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1023870/000089924320019815/doc4.xml","form_type":"4"}}]}